Aardvark Therapeutics, Inc. financial data

Symbol
AARD on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1573% %
Debt-to-equity 9% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21,773,272 shares
Common Stock, Shares, Outstanding 21,745,265 shares
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 21,713,858 shares 445%
Weighted Average Number of Shares Outstanding, Diluted 21,713,858 shares 445%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $13,737,000 USD 238%
General and Administrative Expense $3,966,000 USD 287%
Operating Income (Loss) $17,703,000 USD -248%
Nonoperating Income (Expense) $1,387,000 USD 53%
Net Income (Loss) Attributable to Parent $16,316,000 USD -290%
Earnings Per Share, Basic -0.75 USD/shares 29%
Earnings Per Share, Diluted -0.75 USD/shares 29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $39,285,000 USD
Cash, Cash Equivalents, and Short-term Investments $126,400,000 USD
Assets, Current $129,207,000 USD
Operating Lease, Right-of-Use Asset $439,000 USD
Other Assets, Noncurrent $3,583,000 USD
Assets $133,229,000 USD
Accounts Payable, Current $4,444,000 USD
Employee-related Liabilities, Current $2,150,000 USD
Accrued Liabilities, Current $5,863,000 USD
Liabilities, Current $10,736,000 USD
Operating Lease, Liability, Noncurrent $116,000 USD
Other Liabilities, Noncurrent $0 USD
Liabilities $10,852,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $82,000 USD
Retained Earnings (Accumulated Deficit) $98,320,000 USD
Stockholders' Equity Attributable to Parent $122,377,000 USD
Liabilities and Equity $133,229,000 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,388,000 USD -420%
Net Cash Provided by (Used in) Financing Activities $88,875,000 USD
Net Cash Provided by (Used in) Investing Activities $112,624,000 USD -2252380%
Common Stock, Shares Authorized 490,000,000 shares
Common Stock, Shares, Issued 21,745,265 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39,285,000 USD -52%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $16,231,000 USD -288%
Operating Lease, Liability, Current $429,000 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $5,000 USD 150%
Share-based Payment Arrangement, Expense $1,500,000 USD 942%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares